ORLANDO, Fla.--(BUSINESS WIRE)--Encoded Therapeutics Inc., a clinical-stage biotechnology company developing genetic medicines for severe central nervous system (CNS) disorders, announced today that ...
Encoded Therapeutics Inc. ("Encoded"), a clinical-stage biotechnology company developing precision genetic medicines for severe neurological disorders, today will present new preclinical data across ...
ETX101 reduced seizures and improved neurodevelopmental outcomes, but its impact was unexpectedly attenuated by using the immunosuppressive drug.
Encoded Therapeutics, Inc. (“Encoded”), a clinical‑stage biotechnology company developing precision genetic medicines for severe neurological disorders, today will present an expanded dataset from the ...
Encoded Therapeutics, Inc. ("Encoded"), a clinical-stage biotechnology company developing precision genetic medicines for severe neurological disorders, today announced that the U.S. Food and Drug ...
GW Pharma’s Epidiolex made history in 2018 when the cannabis-based treatment scored an FDA nod for Dravet syndrome, a genetic disorder marked by intractable seizures. But children with Dravet face ...
Encoded Therapeutics reeled in $104 million in series C cash to bankroll the development of its lead program: a precision gene therapy for Dravet syndrome, a rare form of epilepsy. The Bay Area ...
Long non-coding RNAs (lncRNAs) belong to the ever-increasing number of transcripts that are thought not to encode proteins. A recent study has now identified a small polypeptide encoded by the lncRNA ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results